Influence of Cytochrome P450 2D6 Polymorphisms on the Efficacy of Oral Propranolol in Treating Infantile Hemangioma

Wang, Lidan; Zheng, Kai; Xin-lin, LI; Wang, Yang; Xu, Quyi

doi:10.1155/2020/8732871

Cited by 4 publications

(3 citation statements)

References 30 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The gene polymorphism of CYP2D6 (rs1135840) was found to significantly impact the plasma amounts of Propranolol. Patients with the G/G genotype had a better response than those with the C/C genotype [65].…”

Section:  Pharmacological Considerations Regarding Propranolol Therapymentioning

confidence: 87%

Morphological, genetic and clinical correlations in infantile hemangiomas and their mimics

Luca¹,

Miron²,

Trandafir³

et al. 2021

Rom J Morphol Embryol

View full text Add to dashboard Cite

Infantile hemangiomas (IHs) are the most frequent pediatric benign vascular tumors, with a reported incidence of 5% to 10%. They have self-limiting evolution pattern divided into a growth phase in the first 12 months and a regression one, that may take up to 10 years. Occasionally, hemangiomas might lead to local or systemic complications, depending on their morphological characteristics. The first line of treatment is β-blockers, such as Propranolol, Timolol, Nadolol, administered either locally or systemically. Newer therapeutic strategies involving laser therapy and angiotensin-converting enzyme inhibitors are being studied, while older treatment modalities like corticosteroids, Imiquimod, Vincristine, Bleomycin and Interferon-α have become second line therapy options. Before establishing the appropriate treatment, clinical, histological, and imaging investigations are required.

show abstract

Section:  Pharmacological Considerations Regarding Propranolol Therapymentioning

confidence: 87%

Morphological, genetic and clinical correlations in infantile hemangiomas and their mimics

Luca¹,

Miron²,

Trandafir³

et al. 2021

Rom J Morphol Embryol

View full text Add to dashboard Cite

show abstract

“… 46 The effectiveness of propranolol also varied between individuals based on their cytochrome P450 2D6 (CYP2D6) genotype, possibly explaining the difference in treatment response between individuals. 47 A comparison of different treatment durations revealed a better response when oral propranolol was taken for more than 6 months. 45 As to the timing of initiation, ages of 5 weeks to 5 months are suggested, with an exception of premature infants, who would require a corrected age greater than 5 weeks.…”

Section: Reviewmentioning

confidence: 99%

Paediatrics: how to manage infantile haemangioma

Kim¹,

Lam²

2021

DIC

View full text Add to dashboard Cite

Infantile haemangiomas (IHs) are relatively common benign vascular tumours found in the paediatric population. They have varying sizes and involve different depths in the skin leading to various colours, shapes and textures. Although considered harmless in most cases, they may lead to life-threatening complications or cause permanent disfigurations and organ dysfunction. For problematic IHs, the treatment options include oral and topical beta-blockers, systemic corticosteroids, laser treatment, and surgery. In this narrative review, the treatment options for problematic IH are compared and delivered concisely to facilitate the clinical decisions from practitioners, including those in primary care settings. Oral propranolol is currently considered the first-line intervention for problematic IHs. For superficial lesions, there is robust evidence for the use of topical timolol maleate. Systemic corticosteroids are sometimes used in specific situations such as resistance or contraindications to beta-blockers. Surgical excision can be considered in cases requiring urgent intervention such as airway obstruction; this can be done alongside laser therapies for the removal of residual tissue or when reconstructing areas of deformity. The combination of multiple treatment modalities may lead to a more rapid clinical response.

show abstract

“…The beta-blocking effects of propranolol are related to its plasma concentrations ( 6 ). It is uncertain whether the efficacy and safety of propranolol on IH are related to its plasma concentration ( 7 , 8 ).…”

Section: Introductionmentioning

confidence: 99%

Plasma Drug Concentration of Propranolol and Genetic Study in Chinese Han Patients With Infantile Haemangioma

et al. 2022

Front. Pediatr.

View full text Add to dashboard Cite

Background and PurposeThis study was conducted to explore the plasma drug concentration of propranolol in Chinese Han patients with infantile haemangioma (IH) and the influencing factors, as well as the relationship among plasma drug concentrations of propranolol, β1-AR mutation and CYP2D6 188C>T, efficacy, and safety.Experimental ApproachFrom January 2018 to April 2019, 140 patients with IH who were admitted to the hospital for oral propranolol and agreed to have their plasma concentration of propranolol tested, including 112 patients with β1-AR and CYP2D6 gene tested.Key Results and Conclusions and ImplicationsThe mean peak blood levels of propranolol, 4-hydroxypropranolol (4-OH-P), and N-deisopropylpropranolol (NDP) were 60.35 ± 37.90, 1.90 ± 2.37, and 0.24 ± 0.18 ng/ml, respectively. The mean trough blood levels of propranolol, 4-OH-P, and NDP were 24.98 ± 17.68, 0.45 ± 0.52, and 0.05±0.05 ng/ml, respectively. The higher the dose of propranolol, the higher the plasma concentration of propranolol (p = 0.031). The plasma concentration of propranolol was not related to the treatment efficacy.

show abstract

Influence of Cytochrome P450 2D6 Polymorphisms on the Efficacy of Oral Propranolol in Treating Infantile Hemangioma

Cited by 4 publications

References 30 publications

Morphological, genetic and clinical correlations in infantile hemangiomas and their mimics

Morphological, genetic and clinical correlations in infantile hemangiomas and their mimics

Paediatrics: how to manage infantile haemangioma

Plasma Drug Concentration of Propranolol and Genetic Study in Chinese Han Patients With Infantile Haemangioma

Contact Info

Product

Resources

About